View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 13, 2019updated 12 Jul 2022 12:23pm

Signant Health to assist Shanghai Mental Health Center in trial

Shanghai Mental Health Center (SMHC) has selected Signant Health to provide electronic informed consent for a neuroscience study on schizophrenia.

Shanghai Mental Health Center (SMHC) has selected Signant Health to provide electronic informed consent for a neuroscience study on schizophrenia.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The investigator-led trial will enrol patients at different sites in the country and will use Signant’s TrialConsent solution.

TrialConsent will use knowledge quizzes, multimedia videos, self-paced content review and other eConsent methods to help patients and their families understand the risks, benefits and expectations before enrolling in the study.

The platform will benefit the trial as the patients will be engaged. This will result in better retention of patients throughout the duration of the study, Signant Health said.

SMHC will also receive a real-time review of patient compliance and consent data and automated document management, thereby avoiding most consent-related audit findings.

SHMC Department of Psychology vice-director Dr Shen said: “SMHC was confident Signant could support the large-scale investigator-led study involving several hundred subjects across numerous hospital sites, generating significant data. Robust data collection is critical and patient-centric digitisation of the eConsent process will deliver enormous benefit to all stakeholders in this important study.”

Signant CEO Mike Nolte said: “Signant Health’s growing work in Asia supports accelerating demand from life science companies and academic partners in this region for the pioneering services we provide, our deep therapeutic area expertise, scientific and clinical consulting, and data quality analytics that leverage technology to transform the quality and impact of their research studies.”

SMHC is affiliated to the Shanghai Jiao Tong University, research university in China which works on mental health prevention.

Last month, Signant Health launched a new partner programme to collaborate with clinical research organisations (CROs) in a bid to improve clinical trials with patient-centric technology.

CRF Bracket, which was formed as a merged entity of CRF Health and Bracket, was launched as Signant Health in June.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena